About Revago
Clinician-built. Founder-led. Open science.
Revago is the commercial delivery platform for the Autonomic Regulation Protocol (ARP), developed by Marisa Cherry, LCSW.
The ARP started in clinical practice with OCD, anxiety disorders, and PTSD. Across the span of the work — from SPMI to SUD, across every setting — a consistent group emerged: clients who did not respond to top-down therapies or medications. The people who needed the most support were the ones being failed the most often. ARP research began as an effort to find a path for them.
The revelation was that they were all experiencing the same underlying autonomic nervous system dysregulation — a physiological substrate no cognitive or pharmacological intervention had been measuring, let alone treating.
The protocol is now in a preregistered Phase IIa proof-of-concept trial. Revago is the platform that makes it deliverable at scale.
g = 0.00
Effect size for HRV biofeedback on stress and anxiety
Goessl et al., 2017
0%
Average reduction in depression symptoms with HRV biofeedback + therapy
Blase et al., 2021
0%
Of workplace biofeedback studies showing positive outcomes
Ferreira et al., 2025
0+
Countries using HRV biofeedback for law enforcement resilience
Andersen et al., 2024
Founder
Marisa Cherry, LCSW
Founder, Revago · Developer, Autonomic Regulation Protocol (ARP) · ERP & Prolonged Exposure specialist
"The people who needed the most support were the ones being failed the most often. ARP exists for them."